Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and announces Price Target of $35.